Treatment

Displaying 11 - 20 of 375

QVAR RediHaler inhalation aerosol now available

QVAR RediHaler inhalation aerosol now available
Teva Pharmaceutical Industries Ltd. has announced that QVAR RediHaler (beclomethasone dipropionate HFA) Inhalation Aerosol is now commercially available to patients in both 40 mcg and 80 mcg strengths by prescription in the U.S. QVAR RediHaler is the first and only breath-actuated aerosol inhaled corticosteroid for the maintenance treatment of asthma as a prophylactic therapy in patients 4 years of age and older. It is not indicated for the relief of acute bronchospasm.
13th February 2018

The ultimate tumour Terminator

The ultimate tumour Terminator
  In a major advancement in nanomedicine, Arizona State University scientists, in collaboration with researchers from the National Center for Nanoscience and Technology (NCNST) of the Chinese Academy of Sciences, have successfully programmed nanorobots to shrink tumours by cutting off their blood supply.
13th February 2018

Engineers create miniature self-sealing wound

Engineers create miniature self-sealing wound
Biomedical engineers have developed a miniature self-sealing model system for studying bleeding and the clotting of wounds. The researchers envision the device as a drug discovery platform and potential diagnostic tool. A description of the system, and representative movies, are scheduled for publication in Nature Communications. Lead author Wilbur Lam, MD, PhD says that blood clotting involves the damaged blood vessel, platelets, blood clotting proteins that form a net-like mesh, and the flow of the blood itself.
9th February 2018


Edible QR code can be the medicine of the future

Edible QR code can be the medicine of the future
Researchers at the University of Copenhagen have developed a new method for the production of medicine. They print medical drugs in QR coded patterns onto an edible material. The production can be tailored to fit each patient and has the potential to protect against wrong medication and fake medicine according to the researchers. For the last 100 years, researchers have constantly pushed the boundaries for our knowledge about medicine and how different bodies can respond differently to it.
7th February 2018

remedē system receives approval for commercial use

remedē system receives approval for commercial use
Respicardia has announced that the first U.S. commercial case using the remedē System to treat central sleep apnea was completed at The Ohio State University Wexner Medical Center in Columbus, Ohio by Ralph Augostini, MD, FACC, FHRS, Bob and Corrine Frick Chair in Cardiac Electrophysiology, Associate Professor of Medicine and co-director of the electrophysiology training program.
7th February 2018

Strategies of multidrug-resistant chronic infections

Strategies of multidrug-resistant chronic infections
  A new study published in Cell Press finds that antibiotic treatment of chronic infections can be optimised by targeting vulnerabilities of antibiotic-resistant pathogens paving the way for more effective treatment strategies. Antibiotic-resistant Pseudomonas infections in cystic fibrosis patients show predictable sensitivities to other classes of antibiotics.
7th February 2018

Cancer vaccine eliminates tumours in mice

Cancer vaccine eliminates tumours in mice
Injecting minute amounts of two immune-stimulating agents directly into solid tumours in mice can eliminate all traces of cancer in the animals, including distant, untreated metastases, according to a study by researchers at the Stanford University School of Medicine. The approach works for many different types of cancers, including those that arise spontaneously, the study found.
2nd February 2018

Intravenous delivery system for treprostinil

Intravenous delivery system for treprostinil
Current guidelines in the United States and Europe recommend treatment with parenteral prostanoids for severe or rapidly progressing pulmonary arterial hypertension (PAH).2-4 However, risks and complexities associated with the current intravenous (IV) and subcutaneous (SC) delivery systems limit the acceptance of parenteral therapy. IV delivery via an indwelling central venous catheter is associated with the risk of serious bloodstream infections (BSI) and unintended catheter dislodgment, which may be fatal.
1st February 2018

The effects of anti-cancer drug in human cells

The effects of anti-cancer drug in human cells
Researchers at the Institute of Industrial Science (IIS), the University of Tokyo, CNRS and INSERM, report a new organ-on-a-chip technology for the study of blood vessel formation and drugs targeting this event. The technology recreates a human blood vessel and shows how new capillaries grow from a single vessel (parent vessel) in response to proper biochemical signaling cues.
1st February 2018

Target genes to halt progression of thyroid cancer

Target genes to halt progression of thyroid cancer
  Thyroid cancer is a disease with good cure rates in most cases. In 5% of patients, however, the tumour becomes refractory to the available therapies and may spread all over the body, causing death.
1st February 2018


Treatment documents


Sign up to view our publications

Sign up

Sign up to view our downloads

Sign up

Medical Japan 2018
21st February 2018
Japan INTEX Osaka
Med-Tech Innovation Expo 2018
25th April 2018
United Kingdom Ricoh Arena, Coventry